Blog dermatologico

Elenco degli articoli con argomento «ustekinumab»

Brodalumab Achieves Superior Lesion Clearance Compared With Secukinumab and Ustekinumab in Moderate-to-Severe Psoriasis

Rassegna stampa

More patients with moderate-to-severe psoriasis achieved "clear" or "almost clear" status with brodalumab than with secukinumab using Psoriasis Area and Severity (PASI) scores...

Leggi tutto

Switching to Brodalumab From Ustekinumab Improves Clearance in Moderate-to-Severe Psoriasis

Rassegna stampa

Patients with moderate-to-severe psoriasis that did not adequately respond to ustekinumab achieve high levels of lesion clearance after switching to brodalumab rescue therapy...

Leggi tutto

Ixekizumab Superior to Ustekinumab for Treating Psoriasis

Rassegna stampa

Patients with psoriasis treated with the targeted agent ixekizumab appear to have better outcomes at 24 weeks than those treated with ustekinumab, according to the 24-week data of the ongoing IXORA-S trial presented at the 2017 Annual ...

Leggi tutto

Psoriasi, farmaci biologici a tutti i malati?

Rassegna stampa

Se somministrare o meno i nuovi farmaci biologici a tutti i malati di psoriasi è la domanda che ha «tenuto banco» al congresso annuale dell'Accademia Europea di Dermatologia (EADV) che si è da poco concluso a Vienna....

Leggi tutto

Ustekinumab Effective in Treatment of Psoriatic Arthritis With Spondylitis

Rassegna stampa

Ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody approved for the treatment of psoriatic arthritis, shows significant improvement in patients with psoriatric arthritis who also have spondylitis and peripheral joint involveme...

Leggi tutto